Last reviewed · How we verify
intra-arterial tenecteplase — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
intra-arterial tenecteplase (intra-arterial tenecteplase) — ProMedica Health System.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| intra-arterial tenecteplase TARGET | intra-arterial tenecteplase | ProMedica Health System | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- intra-arterial tenecteplase CI watch — RSS
- intra-arterial tenecteplase CI watch — Atom
- intra-arterial tenecteplase CI watch — JSON
- intra-arterial tenecteplase alone — RSS
Cite this brief
Drug Landscape (2026). intra-arterial tenecteplase — Competitive Intelligence Brief. https://druglandscape.com/ci/intra-arterial-tenecteplase. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing